Name: GSK Efimosfermin (FGF21) Catalyst
Start: 2026-04-29

GSK plc

Catalyst AI-extracted

Efimosfermin (FGF21)

liver disease MASH

Resolved

69days ago

Catalyst readout · Apr 29, 2026

What's at stake A key catalyst for Efimosfermin (FGF21) (liver disease MASH) is expected Apr 29, 2026.

Primary source · SEC 6-K verified 13h ago

“Efimosfermin (FGF21) granted US Breakthrough and EU PRIME designations for liver disease MASH.”

1 source on file.

Link copied ✓